Dishman Carbogen Amcis Limited

BSE: 540701 NSE: DCAL
Dishman Carbogen Amcis Limited - pharma in Ahmedabad, Gujarat, India. FY 2026 financials & compliance.
CIN L74900GJ2007PLC051338 Incorporated 17 July 2007 ROC Ahmedabad HQ Ahmedabad, Gujarat, India
Active Listed - NSE: DCAL · BSE: 540701 Public Limited Company pharma
Data last updated
Market Cap
₹2,620 Cr
DCAL · NSE
Share Price
₹167.10
+3.03% today
Revenue
₹2,932 Cr
FY 2025-26 · +8.1% YoY
EBITDA
₹562 Cr
Margin 19.2%
Net Profit
₹98.68 Cr
FY 2025-26 · +639.8% YoY
P/E (TTM)
140.2x
P/B 0.4x
ROE
1.6%
ROCE 2.8%
Debt / Equity
0.44
Interest cover 78.1x

About Dishman Carbogen Amcis Limited

Data last updated:

Dishman Carbogen Amcis Limited is a public limited company based in Ahmedabad, Gujarat, India, a subsidiary of Adimans Technologies Llp. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 17 July 2007 and has been in existence for over 19 years.

Its director Arpit Janmejay Vyas is #1,233 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L74900GJ2007PLC051338. Its GSTIN is 24AADCC1254E1Z9 (Gujarat). The company holds 6 GST registrations, of which 3 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 540701 and NSE: DCAL.

The company has an authorised share capital of ₹38 Cr and a paid-up capital of ₹31.36 Cr. It is led by directors including Arpit Janmejay Vyas (Managing Director) and Deohooti Janmejay Vyas (Whole-Time Director).

Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Dishman Corporate House Iscon – Bopal Road Ambli, Ahmedabad, Gujarat, India – 380058.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹2,931.9 Cr, a growth of 8.1% compared to the previous year. For the same year it recorded a net profit of ₹98.68 Cr (net margin 3.4%) and EBITDA of ₹561.83 Cr (EBITDA margin 19.2%). The net worth stands at ₹6,676.9 Cr (up 14.5% YoY). Total assets are valued at ₹10,912 Cr (up 20.4% YoY).

Its group structure includes 2 subsidiaries.

The company is associated with 2 brands: Dishman Group and Dishman Carbogen Amcis. As per MCA filings, the company has open charges of ₹1,609.35 Cr and satisfied charges of ₹879.25 Cr on record. Court records list 27 cases involving the company, including 14 filed by the company and 13 filed against it; 8 cases are pending. The company has 16 deals on record (14 market trades, 1 buyback, 1 debt financing), with disclosed funding of ₹15 Cr; the latest was in September 2026. Its 5 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations) are compared by revenue, 4 larger and 1 smaller; the largest is Granules India Limited with revenue of ₹4,494.53 Cr. The company has 12 MSME Form 1 returns on record between 2019 and 2024, listing 2,183 overdue payments to 112 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website dishmangroup.com.

Company details

CIN L74900GJ2007PLC051338
Registration Number 051338
Incorporation Date 17 July 2007
ROC Ahmedabad
Listing Status Listed - Listed on NSE (DCAL); Listed on BSE (540701)
Company Status Active
Date of Last AGM 29 September 2025
Date of Balance Sheet 31 March 2026
Parent Company Adimans Technologies Llp
Compliance Status Active Compliant

CIN history

Dishman Carbogen Amcis has one previous CIN (Corporate Identification Number): U74900GJ2007FLC051338. The current CIN is L74900GJ2007PLC051338, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L74900GJ2007PLC051338Current
U74900GJ2007FLC051338Previous
Key People
Arpit Janmejay Vyas Managing Director Deohooti Janmejay Vyas Whole-Time Director Harshil Ramakant Dalal Cfo

Recognitions & Rankings of Dishman Carbogen Amcis

India's Richest People 2026 edition · 1 director · Source: Hurun India

Contact details

Dishman Carbogen Amcis Limited's registered office is in Ahmedabad, Gujarat. Its website is dishmangroup.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    dishmangroup.com
  • Social Media
  • Registered Address
    Dishman Corporate House Iscon – Bopal Road Ambli, Ahmedabad, Gujarat, India – 380058
  • Industry
    Pharma, API Manufacturers

To see the full contact details of Dishman Carbogen Amcis Limited, buy the company report.

Comprehensive company report
Dishman Carbogen Amcis Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Dishman Carbogen Amcis operates two associated brands: Dishman Group and Dishman Carbogen Amcis. Each brand links to its own profile.

BrandDescriptionWebsite
Dishman Group
CDMO offering its services for the development of APIs and intermediatesdishmangroup.com
Dishman Carbogen Amcis
Active pharmaceutical ingredients are manufactured by the CDMO in India.imdcal.com

Business activity

The main business activity of Dishman Carbogen Amcis is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing21Manufacture of basic pharmaceutical products and pharmaceutical preparations

To see the full business activity and turnover split of Dishman Carbogen Amcis Limited, buy the company report.

Financials of Dishman Carbogen Amcis Limited

FY 2025-26 filings available

Dishman Carbogen Amcis Limited reported revenue of ₹2,931.9 Cr (up 8.1% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,932 Cr
+8.1% YoY
EBITDA
₹562 Cr
+24.6% YoY
Profit After Tax
₹98.68 Cr
+639.8% YoY
Net Worth
₹6,677 Cr
+14.5% YoY
Total Assets
₹10,912 Cr
+20.4% YoY
Total Debt
₹3,076 Cr
+28.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,9322,7122,6162,4132,1411,9122,044
Revenue growth+8.1%+3.7%+8.4%+12.7%+12.0%-6.4%-
EBITDA562451280284317252498
EBITDA margin+19.2%+16.6%+10.7%+11.8%+14.8%+13.2%+24.4%
Profit before tax10519.31(122)(54.59)(4.25)(65.03)197
Net profit98.68(18.28)(151)(8.36)49.61(170)163
Net profit margin+3.4%-0.7%-5.8%-0.4%+2.3%-8.9%+8.0%
EPS (₹)6.210.21(9.79)(1.90)1.15(10.53)10.10
Balance sheet
Total assets10,9129,0628,7688,4197,8097,6047,367
Net worth6,6775,8325,6285,8105,5495,6995,715
Total debt3,0762,3892,3132,2091,8301,5891,357
Cash & bank991507413189172308161
Net working capital1,8271,2501,1317828461,017984
Cash flow
Cash from operations491371379266355513585
Cash from investing(245)(192)(225)(494)(619)(380)(442)
Cash from financing201(102)(22.15)250130(11.04)(97.78)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue678851720653708716682789
Revenue growth (YoY)-4.3%+18.9%+5.5%-17.3%+35.2%---
Other income18.1616.426.668.1124.757.977.676.65
EBITDA58.39162113149138141140144
EBITDA margin+8.6%+19.0%+15.7%+22.8%+19.5%+19.7%+20.5%+18.3%
Depreciation90.6888.7984.4284.1381.3579.0971.9772.09
Interest37.0943.3045.7942.3342.7642.1248.7836.63
Profit before tax(51.22)46.13(10.44)30.5438.6727.7027.0542.12
Tax6.6624.392.53(34.73)15.26(15.39)22.429.03
Net profit(57.88)21.74(12.97)65.2723.4143.094.6333.09
EPS (₹)(3.69)1.39(0.83)4.161.492.750.302.11
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue232400327403307200581
Revenue growth-42.1%+22.1%-18.7%+31.3%+53.1%-65.5%-
EBITDA5.3271.793.755.7632.52(59.32)174
EBITDA margin+2.3%+18.0%+1.2%+1.4%+10.6%-29.6%+29.9%
Profit before tax(59.25)(30.83)(103)(96.20)(84.39)(169)55.46
Net profit(39.53)(11.18)(75.39)(56.08)(30.76)(235)42.58
Net profit margin-17.1%-2.8%-23.0%-13.9%-10.0%-117.5%+7.3%
EPS (₹)(2.45)(0.63)(4.87)(3.75)(2.01)(14.85)2.46
Balance sheet
Total assets4,7674,8924,7874,9104,9465,2205,396
Net worth3,8824,0304,0534,1144,2324,6754,796
Total debt634686536593535538573
Cash & bank38.0287.419.9068.4386.4780.3265.13
Net working capital315442325363390511510
Cash flow
Cash from operations46.1155.8124.17(52.90)227(1.51)197
Cash from investing21.68(79.64)96.5740.71(173)62.07(74.30)
Cash from financing(120)87.51(131)1.38(46.16)(70.53)(124)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue57.0868.7239.6860.3062.8610697.0493.29
Revenue growth (YoY)-9.2%-35.2%-59.1%-35.4%-39.2%---
Other income18.8928.837.1011.1737.425.47(8.01)23.93
Total expenses70.5967.7443.1855.8959.4385.5774.0879.89
EBITDA(13.51)0.98(3.50)4.413.4320.5322.9613.40
EBITDA margin-23.7%+1.4%-8.8%+7.3%+5.5%+19.3%+23.7%+14.4%
Depreciation15.3715.1515.1615.7916.4716.1016.4816.30
Interest21.7122.1423.5120.6120.2621.3117.7715.59
Profit before tax(31.70)(7.48)(35.07)(20.82)4.12(11.41)(19.30)5.44
Tax(7.79)(3.14)(11.94)(7.22)1.45(4.04)(6.02)(8.81)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 10 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue678851720653708716682789
Revenue growth (YoY)-4.3%+18.9%+5.5%-17.3%+35.2%---
Other income18.1616.426.668.1124.757.977.676.65
EBITDA58.39162113149138141140144
EBITDA margin+8.6%+19.0%+15.7%+22.8%+19.5%+19.7%+20.5%+18.3%
Depreciation90.6888.7984.4284.1381.3579.0971.9772.09
Interest37.0943.3045.7942.3342.7642.1248.7836.63
Profit before tax(51.22)46.13(10.44)30.5438.6727.7027.0542.12
Tax6.6624.392.53(34.73)15.26(15.39)22.429.03
Net profit(57.88)21.74(12.97)65.2723.4143.094.6333.09
EPS (₹)(3.69)1.39(0.83)4.161.492.750.302.11
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,9322,7122,6162,4132,1411,9122,044
Revenue growth+8.1%+3.7%+8.4%+12.7%+12.0%-6.4%-
Other income55.9421.6828.2127.7743.4238.4544.46
Total expenses2,3702,2612,3352,1291,8241,6601,546
Employee cost1,4471,2941,2081,030981873762
EBITDA562451280284317252498
EBITDA margin+19.2%+16.6%+10.7%+11.8%+14.8%+13.2%+24.4%
Depreciation339294311281308308283
Interest17415912085.6956.8147.6161.95
Profit before tax10519.31(122)(54.59)(4.25)(65.03)197
Tax7.4516.0731.19(24.79)(22.26)10038.69
Net profit98.68(18.28)(151)(8.36)49.61(170)163
Net profit margin+3.4%-0.7%-5.8%-0.4%+2.3%-8.9%+8.0%
EPS (₹)6.210.21(9.79)(1.90)1.15(10.53)10.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital31.3631.3631.3631.3631.3631.3631.38
Reserves & surplus6,6465,8005,5965,7785,5185,6675,684
Shareholders' funds (net worth)6,6775,8325,6285,8105,5495,6995,715
Minority interest0.000.000.000.000.000.000.00
Secured loans2,7302,0721,9461,8251,4211,166916
Unsecured loans346317366384409423442
Total debt3,0762,3892,3132,2091,8301,5891,357
Total liabilities10,9129,0628,7688,4197,8097,6047,367
Assets
Gross block12,41910,55110,3149,4638,6398,1617,896
Net block8,0767,0556,7246,1885,7735,6985,678
Capital work in progress5704676461,043780486234
Investments91.4597.39102249324172191
Inventories1,019900883804645516581
Sundry debtors673665484590473421577
Cash & bank balances991507413189172308161
Loans & advances143103124159256344353
Total current assets2,8262,1751,9051,7411,5461,5881,672
Total current liabilities999925774960700571689
Net working capital1,8271,2501,1317828461,017984
Total assets10,9129,0628,7688,4197,8097,6047,367
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash34126413211024412276.32
Net cash from operating activities491371379266355513585
Net cash from investing activities(245)(192)(225)(494)(619)(380)(442)
Net cash from financing activities201(102)(22.15)250130(11.04)(97.78)
Net change in cash44776.9813221.55(133)12245.62
Closing cash991507413189172308161
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+8.1%+3.7%+8.4%+12.7%+12.0%-6.4%-
EBITDA growth+24.6%+60.8%-1.3%-10.3%+25.7%-49.3%-
PBT growth+443.2%+9998.0%-124.0%-1184.5%+93.5%--36.1%
Net income growth+639.8%+87.9%-1707.3%-116.9%+129.1%-204.4%-
Revenue CAGR (3Y)+6.7%+8.2%+11.0%+5.7%+1.3%+4.1%+6.0%
EBITDA CAGR (3Y)+25.5%+12.5%+3.6%-17.0%-16.9%-17.3%+3.2%
Profitability & leverage
Net income margin+3.3%+0.1%-5.9%-1.2%+0.8%-8.6%+7.8%
Return on capital employed+2.8%+2.2%-0.0%+1.0%+0.8%+0.0%+3.7%
Return on net worth+1.6%-0.3%-2.7%-0.2%+0.9%-3.0%+2.9%
Debt / equity0.440.410.400.360.300.260.22
Long-term debt / equity0.250.170.170.220.180.120.08
Interest cover78.06101.51-393.342,573.27621.55-85.2228.86
Efficiency & per share
Fixed asset turnover0.260.260.260.270.250.240.28
Inventory turnover3.063.043.103.333.693.493.62
Debtors turnover4.384.724.874.544.793.834.00
EPS (₹)6.210.21(9.79)(1.90)1.15(10.53)10.10
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)425.82371.91358.90370.51353.89363.45364.25
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue57.0868.7239.6860.3062.8610697.0493.29
Revenue growth (YoY)-9.2%-35.2%-59.1%-35.4%-39.2%---
Other income18.8928.837.1011.1737.425.47(8.01)23.93
Total expenses70.5967.7443.1855.8959.4385.5774.0879.89
EBITDA(13.51)0.98(3.50)4.413.4320.5322.9613.40
EBITDA margin-23.7%+1.4%-8.8%+7.3%+5.5%+19.3%+23.7%+14.4%
Depreciation15.3715.1515.1615.7916.4716.1016.4816.30
Interest21.7122.1423.5120.6120.2621.3117.7715.59
Profit before tax(31.70)(7.48)(35.07)(20.82)4.12(11.41)(19.30)5.44
Tax(7.79)(3.14)(11.94)(7.22)1.45(4.04)(6.02)(8.81)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue232400327403307200581
Revenue growth-42.1%+22.1%-18.7%+31.3%+53.1%-65.5%-
Other income84.5232.9863.0552.1660.3966.1569.55
Total expenses226328324397274260407
Employee cost86.6390.1591.5486.1379.0458.2388.87
EBITDA5.3271.793.755.7632.52(59.32)174
EBITDA margin+2.3%+18.0%+1.2%+1.4%+10.6%-29.6%+29.9%
Depreciation62.5765.2010296.20140141141
Interest86.5270.4068.1957.9237.2334.1747.02
Profit before tax(59.25)(30.83)(103)(96.20)(84.39)(169)55.46
Tax(20.85)(20.96)(26.59)(37.33)(52.84)64.1216.94
Net profit(39.53)(11.18)(75.39)(56.08)(30.76)(235)42.58
Net profit margin-17.1%-2.8%-23.0%-13.9%-10.0%-117.5%+7.3%
EPS (₹)(2.45)(0.63)(4.87)(3.75)(2.01)(14.85)2.46
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital31.3631.3631.3631.3631.3631.3631.38
Reserves & surplus3,8513,9994,0214,0834,2004,6434,764
Shareholders' funds (net worth)3,8824,0304,0534,1144,2324,6754,796
Secured loans631658524590527526391
Unsecured loans3.5528.0311.743.557.8611.74181
Total debt634686536593535538573
Total liabilities--4,7874,9104,9465,2205,396
Assets
Gross block2,6552,6222,5732,4572,3392,3642,344
Net block1,3721,4011,4161,3821,3561,5101,633
Capital work in progress22.9740.7074.0514311812188.85
Investments2,8442,8412,8482,9133,0322,8822,900
Inventories155134170183197184214
Sundry debtors17117518414765.66119145
Cash & bank balances38.0287.419.9068.4386.4780.3265.13
Loans & advances310263210176196273284
Total current assets674659573574545656708
Total current liabilities359217248211154145197
Net working capital315442325363390511510
Total assets4,7674,8924,7874,9104,9465,2205,396
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash67.734.0514.0724.8816.3626.3328.00
Net cash from operating activities46.1155.8124.17(52.90)227(1.51)197
Net cash from investing activities21.68(79.64)96.5740.71(173)62.07(74.30)
Net cash from financing activities(120)87.51(131)1.38(46.16)(70.53)(124)
Net change in cash(51.80)63.68(10.02)(10.81)8.52(9.97)(1.67)
Closing cash38.0287.419.9068.4386.4780.3265.13
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-42.1%+22.1%-18.7%+31.3%+53.1%-65.5%-
EBITDA growth-92.6%+1814.4%-34.9%-82.3%+154.8%-134.2%-
PBT growth-92.2%+70.1%-7.1%-14.0%+50.0%--32.1%
Net income growth-253.6%+85.2%-34.4%-82.3%+86.9%-652.7%-
Revenue CAGR (3Y)-16.8%+9.3%+17.8%-11.5%-17.7%-25.0%+8.8%
EBITDA CAGR (3Y)-2.6%+30.2%--67.9%-44.8%-+5.4%
Profitability & leverage
Net income margin-16.6%-2.5%-23.3%-14.6%-10.3%-116.2%+6.6%
Return on capital employed0.0%0.0%0.0%0.0%0.0%0.0%+2.0%
Return on net worth0.0%0.0%0.0%0.0%0.0%0.0%+0.9%
Debt / equity0.170.150.140.140.120.120.12
Long-term debt / equity0.050.050.040.040.030.030.04
Interest cover-151.131,068.29-69.68-64.04-34.62-17.03142.79
Efficiency & per share
Fixed asset turnover0.090.150.130.170.130.090.25
Inventory turnover1.602.631.862.121.611.012.66
Debtors turnover1.342.231.983.793.321.524.22
EPS (₹)(2.45)(0.63)(4.87)(3.75)(2.01)(14.85)2.46
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)247.59257.05258.46262.39269.88298.13305.66

To see the full year-wise statements and ratios of Dishman Carbogen Amcis Limited, buy the company report.

Board of directors and KMP of Dishman Carbogen Amcis Limited

Dishman Carbogen Amcis Limited currently reports 6 directors and 1 key managerial person. 8 former directors have served the organization.

Current Directors and KMP
NameDesignationAppointment DateTenureStatus
Arpit Janmejay Vyas
Also directs: Dishman Biotech Limited, RTV Technochem Private Limited, Leon Hospitality Private Limited and 5 more
Managing Director07 Apr 201214 Years 7 MonthsCurrent
Harshil Ramakant Dalal
Also directs: Dishman Medicare Limited, Aham Brahmasmi Entertainment Private Limited
Cfo28 Nov 20187 Years 11 MonthsCurrent
Deohooti Janmejay Vyas
Also directs: Adimans Technologies LLP, B R Laboratories Limited, Dishman Biotech Limited and 5 more
Whole-Time Director17 Mar 20179 Years 7 MonthsCurrent
Dhaval Rameshchandra ShahDirector12 Aug 20251 Years 2 MonthsCurrent
Hemantkumar Jayantiprasad Bhatt
Also directs: Transpek Creative Chemistry Private Limited
Director01 Apr 20251 Years 7 MonthsCurrent
Margie ParikhDirector01 Apr 20251 Years 7 MonthsCurrent
Showing 6 of 7 current directors and KMP. View all directors and KMP

Peer comparison

Dishman Carbogen Amcis Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Granules India Limited₹4,494.53 Cr (FY 2025)0.0%Hyderabad, Telangana, India
Matrix Pharmacorp Private Limited₹4,422.21 Cr (FY 2025)16378466.0%Sangareddy, Telangana, India
Cadila Pharmaceuticals Limited₹3,869.17 Cr (FY 2025)4.0%Ahmedabad, Gujarat, India
Hetero Drugs Limited₹3,323.92 Cr (FY 2025)13.0%Hyderabad, Telangana, India
Dishman Carbogen Amcis Limitedthis company₹2,931.9 Cr (FY 2026)₹98.68 Cr3.4%8.1%Ahmedabad, Gujarat, India
Alivus Life Sciences Limited₹2,421.45 Cr (FY 2025)5.0%Solapur, Maharashtra, India

To see the full peer comparison of Dishman Carbogen Amcis Limited, buy the company report.

Auditor

Dishman Carbogen Amcis Limited is audited by T R Chadha & Co. LLP for the financial year 2025.

Auditor firmFinancial yearFirm registration number
T R Chadha & Co. LLPFY 2025006711N/N500028

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 59.30%, foreign institutional investors hold 6.90%, domestic institutional investors hold 2.00% and retail and other public shareholders hold 31.80%.

Promoters: 59.30%DII (Domestic Institutional): 2.00%FII (Foreign Institutional): 6.90%Retail & Others: 31.80%
Sep 2026
QUARTER
59.30% Promoters
2.00% DII (Domestic Institutional)
6.90% FII (Foreign Institutional)
31.80% Retail & Others
Promoter holding - history
Now 59.30% · Sep 2026High 59.30% · Dec 2025Low 59.30% · Dec 2025
58%58.8%59.5%60.3%61%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 59.30%Mar 2026: 59.30%Jun 2026: 59.30%Sep 2026: 59.30%59.30%59.30%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters59.30%59.30%59.30%59.30%
Public40.70%40.70%40.70%40.70%

Charges & borrowings

Open charges
₹1,609.35 Cr
Satisfied charges
₹879.25 Cr
Breakdown by lending institutions
Others₹1,557.41 Cr
Axis Bank Limited₹47.97 Cr
Hdfc Bank Limited₹3.92 Cr
Madhya Pura Mercentile Co.Op. Bank₹0.05 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
30 Jun 2026101316108Others₹42.85 CrOpen
30 Mar 2026101278652Others₹60 CrOpen
10 Feb 2026101242915Others₹75 CrOpen
17 Jan 2026101243205Others₹50 CrOpen
13 Jan 2026101228176Others₹20 CrOpen

To see the full charge records of Dishman Carbogen Amcis Limited, buy the company report.

Total charge records: 47 View all charges

Deals & funding

Dishman Carbogen Amcis Limited has 16 deals on record (14 market trades, 1 buyback, 1 debt financing), with disclosed funding of ₹15 Cr; the latest was in September 2026.

Total deals
16
Market trades
14
Buyback
1
Debt financing
1
Disclosed funding
₹15 Cr

Deals on record (5 of 16)

WhenDealAmountParties
Dec 2024Market trade₹34.05 CrBuyer: Crony Vyapar Private Limited
Seller: Crony Vyapar Private Limited
Dec 2024Market trade₹37.01 CrBuyer: Crony Vyapar Private Limited
Seller: Crony Vyapar Private Limited
Mar 2024Market trade₹24.05 CrBuyer: Crony Vyapar Private Limited
Seller: Crony Vyapar Private Limited
Mar 2024Market trade₹27.44 CrBuyer: Crony Vyapar Private Limited
Seller: Crony Vyapar Private Limited
Dec 2023Market trade₹16.02 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP

To see the full deal history of Dishman Carbogen Amcis Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Dishman Carbogen Amcis Limited was last rated by Indiarating on 26 Oct 2021.

Rating agencyRated onRating
Indiarating26 Oct 2021

To see the full credit ratings and regulatory alerts of Dishman Carbogen Amcis Limited, buy the company report.

MSME payment delays

Dishman Carbogen Amcis Limited has 12 MSME Form 1 returns on record between 2019 and 2024, listing 2,183 overdue payments to 112 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 112)

SupplierAmount dueDue sinceReported on
an individual supplier
an individual supplier
Rachna Air Components Private Limited
Agile Diagnostics
V. Jashvantlal & Co.

To see the full MSME payment records of Dishman Carbogen Amcis Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Dishman Carbogen Amcis has 2 subsidiary companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

2
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Dishman Biotech LimitedU24231GJ1995PLC028060
Dishman Medicare Limited (Formerly Known As Visible Investment Limited)U65990GJ2021PLC122015

To see the full group structure of Dishman Carbogen Amcis Limited, buy the company report.

GST

Dishman Carbogen Amcis has 6 GST registrations: 3 active and 3 cancelled or inactive.

Total GSTINs
6
Active
3
Cancelled / inactive
3
GSTINStateStatusRegistered on
24AADCC1254E1Z9GujaratActive01 Jul 2017
24AADCC1254E3Z7GujaratActive04 Jul 2017
27AADCC1254E1Z3MaharashtraActive01 Jul 2017

To see the full GST registrations and return filing status of Dishman Carbogen Amcis Limited, buy the company report.

Recent activity

Dishman Carbogen Amcis Limited has 23 board changes on record since 2007: 15 appointments and 8 cessations. The latest: Dhaval Rameshchandra Shah was appointed as Director on 12 Aug 2025.

Charges
A charge with Others amounted to Rs. 42.85 Cr with Charge ID 101316108 was registered on 30 Jun 2026.
Filing
Dishman Carbogen Amcis Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Charges
A charge with Others amounted to Rs. 60.00 Cr with Charge ID 101278652 was registered on 30 Mar 2026.
Charges
A charge with Others amounted to Rs. 75.00 Cr with Charge ID 101242915 was registered on 10 Feb 2026.
Charges
A charge registered on 18 May 2023 via Charge ID 100729014 with Others was fully satisfied on 29 Jan 2026.
Charges
A charge registered on 10 Nov 2022 via Charge ID 100646576 with Others was fully satisfied on 29 Jan 2026.
Charges
A charge registered on 21 Dec 2021 via Charge ID 100534456 with Others was fully satisfied on 29 Jan 2026.
Charges
A charge registered on 18 Feb 2020 via Charge ID 100330187 with Others was fully satisfied on 29 Jan 2026.
Charges
A charge with Others amounted to Rs. 50.00 Cr with Charge ID 101243205 was registered on 17 Jan 2026.
Charges
A charge with Others amounted to Rs. 20.00 Cr with Charge ID 101228176 was registered on 13 Jan 2026.
Charges
A charge with Others of Rs. 385.33 Cr registered on 19 Oct 2007 with Charge ID 10072442 was modified on 31 Dec 2025.
Charges
A charge with Others of Rs. 385.33 Cr registered on 19 Jan 1999 with Charge ID 90098942 was modified on 31 Dec 2025.

85 earlier events are in the company report.

News

Dishman Carbogen: Co's Unit Successfully Finishes US FDA Inspection At Switzerland Facility With No Issues.
15 Sep 2026 · Exchange Update

Frequently asked questions

Dishman Carbogen Amcis is an active public limited company based in Ahmedabad, Gujarat, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 17 July 2007 (19+ years old) and is registered under CIN L74900GJ2007PLC051338. Listed on BSE: 540701 and NSE: DCAL.

Dishman Carbogen Amcis reported revenue of ₹2,931.9 Cr for FY 2025-26 (up 8.1% YoY) based on consolidated financials.

Dishman Carbogen Amcis has 7 current directors and KMP:

The latest financial statements of Dishman Carbogen Amcis on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 29 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Dishman Carbogen Amcis is 24AADCC1254E1Z9, registered in Gujarat. The company has 6 GST registrations in all, of which 3 are active and 3 are cancelled or inactive. Other active GSTINs include 24AADCC1254E3Z7 (Gujarat), 27AADCC1254E1Z3 (Maharashtra).

The CIN (Corporate Identification Number) of Dishman Carbogen Amcis is L74900GJ2007PLC051338. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Dishman Carbogen Amcis is a listed company as per MCA records. Its shares are listed on both BSE (code: 540701) and NSE (symbol: DCAL).

Dishman Carbogen Amcis has 27 court cases on record: 14 filed by the company and 13 filed against it. 8 are pending. Most are in the district courts.

Dishman Carbogen Amcis was incorporated on 17 July 2007, making it 19+ years old. It is registered with the Registrar of Companies, Ahmedabad.

Dishman Carbogen Amcis has 16 deals on record (14 market trades, 1 buyback, 1 debt financing), with disclosed funding of ₹15 Cr; the latest was in September 2026.

The peers of Dishman Carbogen Amcis by revenue are Granules India Limited, Matrix Pharmacorp Private Limited, Cadila Pharmaceuticals Limited, Hetero Drugs Limited, Alivus Life Sciences Limited, all in the Pharma industry (API Manufacturers), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations).

Dhaval Rameshchandra Shah was appointed as Director on 12 Aug 2025. Janmejay Rajnikant Vyas ceased to be Director on 27 May 2025. Rajendra Shantilal Shah ceased to be Director on 02 Apr 2025. Dishman Carbogen Amcis has 23 board changes on record in total.